Turning the tide or riptide? The changing opioid epidemic

Substance Abuse

Volumn 38, Issue 1, 2017, Pages 3-8

  Kertesz, Stefan G ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

opioid use disorder; Opioids; overdose; pain; prescriptions; primary care; treatment access

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ALABAMA; DRUG OVERDOSE; HUMAN; PRESCRIPTION DRUG MISUSE; STATISTICS AND NUMERICAL DATA; TRENDS;

ALABAMA; ANALGESICS, OPIOID; DRUG OVERDOSE; HUMANS; PRESCRIPTION DRUG MISUSE;

EID: 85006918704     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2016.1261070     Document Type: Note

References (53)

1. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
2. Saha TD, Kerridge BT, Goldstein RB, et al. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J Clin Psychiatry. 2016;77:772–780.
3. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1–49.
4. US Food and Drug Administration. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death. FDA News Release. March 22, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm. Accessed October 28, 2016.
5. Johnson K. Exclusive:Obama administration to launch new effort on heroin crisis. USA Today. 2016. http://www.usatoday.com/story/news/politics/2016/09/16/heroin-justice-department-lynch-obama-administration/90421316/. Accessed September16, 2016.
6. Drug Enforcement Administration Public Affairs. DEA Reduces Amount of Opioid Controlled Substances to be Manufactured in 2017. Washington, DC:US Drug Enforcement Administration. https://www.dea.gov/divisions/hq/2016/hq100416.shtml. Published October 12, 2016. Accessed October14, 2016.
7. Davey N. Congress Must Do More to Address the U.S. Opioid Epidemic. Center for American Progress. https://www.americanprogress.org/issues/healthcare/news/2016/08/25/143020/congress-must-do-more-to-address-the-u-s-opioid-epidemic/. Published August 25, 2016. Accessed October2, 2016.
8. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis:a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559–574.
9. Jones CM, Lurie PG, Throckmorton DC. Effect of US Drug Enforcement Administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Intern Med. 2016;176:399–402.
10. Goodnough A, Tavernise S. Opioid prescriptions drop for first time in two decades. New York Times. 2016. http://www.nytimes.com/2016/05/21/health/opioid-prescriptions-drop-for-first-time-in-two-decades.html?_r=0. Accessed May20, 2016.
11. Khemlani A. Shulkin:VA's inroads in treatment of opioid abuse could be example for N.J., elsewhere. NJBIZ. August 9, 2016. http://www.njbiz.com/article/20160809/NJBIZ01/160809789/shulkin-vas-inroads-in-treatment-of-opioid-abuse-could-be-example-for-nj-elsewhere. Accessed September25, 2016.
12. Office of Applied Studies Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health:Detailed Tables. Rockville, MD:US Department of Health and Human Services. http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf. Published September 10, 2015. Accessed October2, 2016.
13. Miech RA, Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future:National Survey Results on Drug Use (1975–2015) Volume 1, Secondary School Students. Ann Arbor, MI:Institute for Social Research, The University of Michigan; 2016. http://monitoringthefuture.org//pubs/monographs/mtf-vol1_2015.pdf. Accessed October16, 2016.
14. Gladden RM MP, Seth P. Fentanyl law enforcement submissions and increases in synthetic opioid–involved overdose deaths—27 states, 2013–2014. MMWR Morb Mortal Wkly Rep. 2016;65:837–843.
15. National Center for Health Statistics. Percent of drug poisoning deaths that mention the type of drug(s) involved, by state:2013–2014. Atlanta, GA:Centers for Disease Control and Prevention; n.d. http://www.cdc.gov/nchs/data/health_policy/unspecified_drugs_by_state_2013-2014.pdf. Accessed September17, 2016.
16. Drug Enforcement Administration Strategic Intelligence Section. National Heroin Threat Assessment Summary—Updated. Washington, DC:US Drug Enforcement Administration. https://www.dea.gov/divisions/hq/2016/hq062716_attach.pdf. Published June 2016. Accessed October5, 2016.
17. US Drug Enforcement Administration Office of Diversion Control. Special Report:Opiates and Related Drugs Reported in NFLIS, 2009–2014. Springfield, VA:US Drug Enforcement Adminsitration. https://www.deadiversion.usdoj.gov/nflis/spec_rpt_opioids_2014.pdf. Published January 2016. Accessed October15, 2016.
18. Centers for Disease Control Health Alert Network. Increases in Fentanyl Drug Confiscations and Fentanyl-Related Overdose Fatalities. Atlanta, GA:Centers for Disease Control. https://stacks.cdc.gov/view/cdc/35133. Published October 26, 2015. Accessed October2, 2016.
19. Jefferson County Coroner/Medical Examiner's Office. Requirements and Guidelines for Notification of Death Pursuant to Alabama Act 79-454. Birmingham, AL:Jefferson County Coroner/Medical Examiner's Office. http://jeffconline.jccal.org/Sites/Jefferson_County/Documents/Coroner_MedicalExaminer Office/RequirementsandGuidelinesforNotificationofDeath.pdf. Published October 21, 2015. Accessed October1, 2016.
20. Jefferson County Coroner/Medical Examiner's Office. Annual Report:2015. Birmingham, AL:Jefferson County Coroner/Medical Examiner's Office. http://jeffconline.jccal.org/Sites/Jefferson_County/Documents/Coroner_MedicalExaminerOffice/2015Annual Report.pdf. Published May 2016. Accessed August15, 2016.
21. Cuyahoga County Medical Examiner's Office. Heroin & Fentanyl Related Deaths in Cuyahoga County. Cleveland, OH:Cuyahoga County Medical Examiner's Office. http://medicalexaminer.cuyahogacounty.us/pdf_medicalexaminer/en-US/August2016-HeroinFentanylUpdate.pdf. Published September 7, 2016. Accessed xxx.
22. Bharel M. An Assessment of Opioid-Related Deaths in Massachusetts (2013–2014). Boston:Massachusetts Department of Public Health. http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/chapter-55-overdose-assessment.html. Published September 15, 2016. Accessed October2, 2016.
23. Kolodny A. Crooked doctors are not fueling the opioid epidemic. New York Times. February 17, 2016. http://www.nytimes.com/roomfordebate/2016/02/17/prosecuting-doctors-in-prescription-drug-overdose-deaths/crooked-doctors-are-not-fueling-the-opioid-epidemic. Accessed October5, 2016.
24. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain:a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276–286.
25. Lembke A. Why doctors prescribe opioids to known opioid abusers. N Engl J Med. 2012;367:1580–1581.
26. Paulozzi LJ, Jones CM, Mack KA, Rudd RA. Vital signs:overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60:1487–1492.
27. Martin SA, Potee RA, Lazris A. Neat, plausible, and generally wrong:a response to the CDC recommendations for chronic opioid use. Medium.com Web site. https://medium.com/@stmartin/neat-plausible-and-generally-wrong-a-response-to-the-cdc-recommendations-for-chronic-opioid-use-5c9d9d319f71#.kclqvd5bg. Published September 7, 2016. Accessed September7, 2016.
28. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–1756.
29. Bachman JG, O'Malley PM, Schulenberg JE, Johnston LD, Bryant AL, Merline AC. The Decline of Substance Use in Young Adulthood:Changes in Social Activities, Roles, and Beliefs. Mahwah, NJ:Erlbaum; 2002.
30. Committee on Opportunities in Drug Abuse Research. Pathways of Addiction:Opportunities in Drug Abuse Research. Washington, DC:National Academies Press; 1996.
31. US Drug Enforcement Administration Office of Diversion Control. National Forensic Laboratory Information System:Midyear Report 2015. Springfield, VA:US Drug Enforcement Administration. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS_MidYear2015.pdf. Accessed October15, 2016.
32. Drug Enforcement Administration Philadelphia Field Division. Analysis of Drug-Related Overdose Deaths in Pennsylvania, 2015. Philadelphia, PA:US Drug Enforcement Administration. https://www.dea.gov/divisions/phi/2016/phi071216_attach.pdf. Published July 2016. Accessed October2, 2016.
33. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63.
34. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
35. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209.
36. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103:462–468.
37. Substance Abuse and Mental Health Services Administration. FY 2016–17 Block Grant Application:Community Mental Health Services Plan and Report Substance Abuse Prevention and Treatment Plan and Report. Washington, DC:US Department of Health and Human Services. http://www.samhsa.gov/sites/default/files/grants/bg-application-fy-16-17.pdf. Accessed October15, 2016.
38. Substance Abuse and Mental Health Services Administration. Targeted Capacity Expansion:Medication Assisted Treatment—Prescription Drug and Opioid Addiction (MAT-PDOA). Washington, DC:US Department of Health and Human Services. http://www.samhsa.gov/grants/grant-announcements/ti-16-014. Published March 29, 2016. Accessed October10, 2016.
39. Hoffman J. Patients in pain, and a doctor who must limit drugs. New York Times. March 16, 2016. http://www.nytimes.com/2016/03/17/health/er-pain-pills-opioids-addiction-doctors.html?_r=0. Accessed October16, 2016.
40. Anson P. Survey:Opioids Reduced or Stopped for Most Patients. Pain News Network Web site. http://www.painnewsnetwork.org/stories/2016/8/4/survey-opioids-stopped-or-reduced-for-most-patients. Published August 4, 2016. Accessed August4, 2016.
41. Kropf K. “Today I have chosen to draw the line”. Athenainsight Web site. https://insight.athenahealth.com/ohio-faces-the-opioid-crisis-the-journals-of-katy-kropf-d-o/. Accessed September28, 2016.
42. Kirby L. Suicide. Part 2:a father's story of his loving step-daughter's suicide due to lack of adequate pain control. Rally Against Pain Web site. https://rallyagainstpain.com/2016/09/30/suicide-part-2-a-fathers-story-of-his-loving-step-daughters-suicide-due-to-lack-of-adequate-pain-control/. Published September 30, 2016. Accessed September30, 2016.
43. Drug Enforcement Administration Strategic Intelligence Section. Counterfeit Prescription Pills Containing Fentanyls:A Global Threat. McLean, VA:US Drug Enforcement Administration. https://www.dea.gov/docs/CounterfeitPrescriptionPills.pdf. Published July 2016. Accessed October15, 2016.
44. Webster LR. Pain and suicide:the other side of the opioid story. Pain Med. 2014;15:345–346.
45. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321.
46. Campbell CI, Weisner C, Leresche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health. 2010;100:2541–2547.
47. Turner JA, Shortreed SM, Saunders KW, LeResche L, Von Korff M. Association of levels of opioid use with pain and activity interference among patients initiating chronic opioid therapy:a longitudinal study. Pain. 2016;157:849–857.
48. Frieden TR. Transcript for CDC Telebriefing:Guideline for Prescribing Opioids for Chronic Pain. Atlanta, GA:Centers for Disease Control and Prevention. http://www.cdc.gov/media/releases/2016/t0315-prescribing-opioids-guidelines.html. Published March 15, 2016. Accessed October13, 2016.
49. Young R. Where Chronic Pain Patients Fit Into the Opioid Crisis. Boston:WBUR. http://www.wbur.org/hereandnow/2016/02/15/chronic-pain-patients-opioids. Published February 16, 2016. Accessed October19, 2016.
50. Richmond H, Hall AM, Copsey B, et al. The effectiveness of cognitive behavioural treatment for non-specific low back pain:a systematic review and meta-analysis. PLoS ONE. 2015;10:e0134192.
51. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev. 2013;(8):CD004959.pub4.
52. IMS Institute for Healthcare Informatics. Use of Opioid Recovery Medications:Recent Evidence on State Level Buprenorphine Use and Payment Types. Parsippany, NJ:IMS Institute for Healthcare Informatics. https://www.imshealth.com/files/web/IMSHInstitute/Reports/HealthcareBriefs/IIHI_Use_of_Opioid_Recovery_Medications.pdf. Published September 2016. Accessed October5, 2016.
53. Matthew 27:24. The Holy Bible:New Revised Standard Version with Apocrypha. New York:Oxford University Press; 1989.